Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nurix Therapeutics (NRIX)
NASDAQ:NRIX
Nurix Therapeutics (NRIX) Stock Price & Analysis
359 Followers
NRIX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.22 - $18.12
Previous Close$16.59
Volume3.04M
Average Volume (3M)1.11M
Market Cap
$984.08M
Enterprise Value$963.42M
Total Cash (Recent Filing)$49.81M
Total Debt (Recent Filing)$29.16M
Price to Earnings (P/E)-6.3
Beta1.27
Next Earnings
Jul 10, 2024EPS Estimate
-$0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.65
Shares Outstanding49,150,794
10 Day Avg. Volume939,501
30 Day Avg. Volume1,114,061
Standard Deviation0.24
R-Squared0.20
Alpha-0.00916
Financial Highlights & Ratios
Price to Book (P/B)4.49
Price to Sales (P/S)49.17
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.91
Enterprise Value/Gross Profit12.51
Enterprise Value/Ebitda-7.04
Forecast
1Y Price Target
$24.67Price Target Upside48.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Nurix Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPositive clinical trial results for NX-5948 show a 70% overall response rate in CLL patients, highlighting the drug's potential effectiveness.
Innovation And Market PotentialNurix Therapeutics' innovative approach in Targeted Protein Modulation and collaborations with large pharmaceutical companies underscore strong market confidence and future potential.
Strategic PartnershipsThe extension of Nurix's collaboration with Gilead and a promising drug target IRAK4 reflects the value and potential of Nurix's strategic partnerships within the industry.
Bears Say
Clinical DevelopmentA patient with primary central nervous system lymphoma experienced disease progression with a new brain lesion after initial complete response to NX-5948.
Financial PerformanceNurix reported a net loss of $2.65 per share, a significant deviation from the anticipated net gain of $0.26 per share, primarily due to lower-than-expected collaboration revenue.
Regulatory ChallengesNX-2127 remains on partial clinical hold, indicating some regulatory challenges and uncertainties in the drug's development pipeline.
---
Ownership Overview
14.90% Insiders
19.18% Mutual Funds
59.69% Other Institutional Investors
6.23% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NRIX FAQ
What was Nurix Therapeutics’s price range in the past 12 months?
Nurix Therapeutics lowest stock price was $4.22 and its highest was $18.12 in the past 12 months.
What is Nurix Therapeutics’s market cap?
Currently, no data Available
When is Nurix Therapeutics’s upcoming earnings report date?
Nurix Therapeutics’s upcoming earnings report date is Jul 10, 2024 which is in 52 days.
How were Nurix Therapeutics’s earnings last quarter?
Nurix Therapeutics released its earnings results on Apr 10, 2024. The company reported -$0.76 earnings per share for the quarter, beating the consensus estimate of -$0.776 by $0.016.
Is Nurix Therapeutics overvalued?
According to Wall Street analysts Nurix Therapeutics’s price is currently Undervalued.
Does Nurix Therapeutics pay dividends?
Nurix Therapeutics does not currently pay dividends.
What is Nurix Therapeutics’s EPS estimate?
Nurix Therapeutics’s EPS estimate is -$0.66.
How many shares outstanding does Nurix Therapeutics have?
Nurix Therapeutics has 59,317,460 shares outstanding.
What happened to Nurix Therapeutics’s price movement after its last earnings report?
Nurix Therapeutics reported an EPS of -$0.76 in its last earnings report, beating expectations of -$0.776. Following the earnings report the stock price went down -10.24%.
Which hedge fund is a major shareholder of Nurix Therapeutics?
Among the largest hedge funds holding Nurix Therapeutics’s share is Baker Bros Advisors LP. It holds Nurix Therapeutics’s shares valued at 40M.
---
Nurix Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.67 (48.70% Upside)
$24.67 (48.70% Upside)
Blogger Sentiment
Bullish
NRIX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 617.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.73%
12-Months-Change
Fundamentals
Return on Equity
-65.37%
Trailing 12-Months
Asset Growth
-15.53%
Trailing 12-Months
Company Description
Nurix Therapeutics
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
---
NRIX Stock 12 Month Forecast
Average Price Target
$24.67
▲(48.70% Upside)
Technical Analysis
Best Analysts Covering NRIX
1 Year
1 Year Success Rate
9/13 ratings generated profit
1 Year Average Return
+39.55%
reiterated a buy rating last month
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +39.55% per trade.
---